These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10117563)

  • 1. FDA withholds approval of anti-infection drug; manufacturer's stock price plunges.
    Wagner M
    Mod Healthc; 1992 Apr; 22(16):6. PubMed ID: 10117563
    [No Abstract]   [Full Text] [Related]  

  • 2. Centacor stock dips again after articles on Centoxin.
    Wagner M
    Mod Healthc; 1992 Apr; 22(17):20. PubMed ID: 10117574
    [No Abstract]   [Full Text] [Related]  

  • 3. Company stock prices before and after public announcements related to oncology drugs.
    Rothenstein JM; Tomlinson G; Tannock IF; Detsky AS
    J Natl Cancer Inst; 2011 Oct; 103(20):1507-12. PubMed ID: 21949081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spinning the wheel on ImClone.
    Varchaver N
    Fortune; 2003 Apr; 147(8):123-5. PubMed ID: 12728651
    [No Abstract]   [Full Text] [Related]  

  • 5. Sporicidin responds to the recall of its products.
    Healthc Hazard Mater Manage; 1992 Aug; 5(11):8-11. PubMed ID: 10121070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AHP's awful losing streak.
    Whitford D
    Fortune; 1999 Nov; 140(10):52, 56. PubMed ID: 10662389
    [No Abstract]   [Full Text] [Related]  

  • 7. The drug that could have been.
    Schultz S
    US News World Rep; 2002 Aug; 133(7):18, 20-3. PubMed ID: 12195678
    [No Abstract]   [Full Text] [Related]  

  • 8. Adoption agent.
    Peota C
    Minn Med; 2005 Mar; 88(3):8-9. PubMed ID: 15852583
    [No Abstract]   [Full Text] [Related]  

  • 9. The Sporicidin recall.
    Healthc Hazard Mater Manage; 1992 Jan; 5(4):9-11. PubMed ID: 10116667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Security market reaction to FDA fast track designations.
    Anderson CW; Zhang Y
    J Health Care Finance; 2010; 37(2):27-48. PubMed ID: 21294437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Veridien expects FDA approval soon on HIV virus-killing Sterihol.
    Ostomy Wound Manage; 1993 May; 39(4):65-6. PubMed ID: 8363719
    [No Abstract]   [Full Text] [Related]  

  • 12. Vouchers for FDA priority reviews.
    Spatz ID
    Health Aff (Millwood); 2006; 25(4):1184; author reply 1184-5. PubMed ID: 16835203
    [No Abstract]   [Full Text] [Related]  

  • 13. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
    Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR
    Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
    [No Abstract]   [Full Text] [Related]  

  • 15. Sporicidin update: are the government's regulatory teeth tearing a hole in industry?
    Healthc Hazard Mater Manage; 1993 Apr; 6(7):10-1. PubMed ID: 10125098
    [No Abstract]   [Full Text] [Related]  

  • 16. Biotech's next big blowup?
    Stires D
    Fortune; 2002 Mar; 145(6):154. PubMed ID: 11913033
    [No Abstract]   [Full Text] [Related]  

  • 17. Great company, bad stock.
    Jacobs T
    Nat Biotechnol; 2005 Feb; 23(2):173. PubMed ID: 15696142
    [No Abstract]   [Full Text] [Related]  

  • 18. EMEA approves OGS drug rejected by FDA.
    Mitchell P
    Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490
    [No Abstract]   [Full Text] [Related]  

  • 19. Antibiotics--an investment worth making?
    Christoffersen RE
    Nat Biotechnol; 2006 Dec; 24(12):1512-4. PubMed ID: 17160052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When your stock takes a nosedive.
    Jacobs T
    Nat Biotechnol; 2006 Feb; 24(2):144. PubMed ID: 16465152
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.